



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson, Inc.  
(310) 279-5963

**SOMAXON PHARMACEUTICALS TO REPORT 2006 THIRD QUARTER  
FINANCIAL RESULTS AND HOST CONFERENCE CALL  
ON NOVEMBER 9, 2006**

**SAN DIEGO, CA – November 2, 2006** – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2006 third quarter financial results after the market closes on Thursday, November 9, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions.

The conference call will be available to interested parties through live audio Internet broadcast at [www.somaxon.com](http://www.somaxon.com) and [www.opencompany.info](http://www.opencompany.info). The call will also be archived and accessible at both sites for approximately 14 days. Alternatively, callers may participate in the conference call by dialing (800) 219-6110 (domestic) or (303) 262-2142 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering passcode 11074051.

**About Somaxon Pharmaceuticals, Inc.**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

###